Friday, December 5, 2025
ADVT 
Health

Health Canada approves updated Pfizer, Moderna COVID-19 vaccines for fall

Darpan News Desk The Canadian Press, 22 Aug, 2025 01:01 PM
  • Health Canada approves updated Pfizer, Moderna COVID-19 vaccines for fall

Health Canada has authorized updated COVID-19 vaccines by Pfizer and BioNTech and by Moderna for use this respiratory virus season.

Moderna says it will manufacture vaccine doses for the Canadian market in its new facility in Laval, Quebec and syringes will be filled in Cambridge, Ontario.

News releases from both Pfizer and Moderna say the new mRNA shots will target the LP.8.1 variant, a descendant of Omicron that the World Health Organization was monitoring earlier this year.

Both Pfizer's vaccine — called Comirnaty — and Moderna's shot — called Spikevax — are approved for adults and children six months of age and older.

The provinces and territories are responsible for ordering COVID-19 vaccines and deciding who will get them free of charge.

The National Advisory Committee on Immunization recommends seniors, residents of long-term care homes, people who are immunocompromised, health-care workers and people at risk of severe COVID-19 illness get vaccinated.

It recommends two doses of the vaccine per year for people 80 years of age and older, long-term care residents and people six months of age and older who are moderately to severely immunocompromised.

The advisory committee recommends one shot per year for people between 65 and 79 years of age, health-care workers and people at risk of getting severely ill from COVID-19.

NACI says those considered at higher risk include those with underlying medical conditions; people who are pregnant, people from First Nations, Inuit and Métis communities; and members of racialized communities.

Picture Courtesy: THE CANADIAN PRESS/Ryan Remiorz

MORE Health ARTICLES

ER visits down 25 per cent in early 2020: report

ER visits down 25 per cent in early 2020: report
A new report finds emergency department visits dropped by 25 per cent in the early days of the COVID-19 pandemic.

ER visits down 25 per cent in early 2020: report

UN cautions that virus plasma treatment still experimental

UN cautions that virus plasma treatment still experimental
The World Health Organization on Monday cautioned that using blood plasma from COVID-19 survivors to treat other patients is still considered an experimental therapy, voicing the concern as a U.S. boost for the treatment has many scientists afraid formal studies will be derailed.

UN cautions that virus plasma treatment still experimental

Pandemic pushes expansion of 'hospital-at-home' treatment

Pandemic pushes expansion of 'hospital-at-home' treatment
As hospitals care for people with COVID-19 and try to keep others from catching the virus, more patients are opting to be treated where they feel safest: at home.

Pandemic pushes expansion of 'hospital-at-home' treatment

Pharmacists can give childhood shots, U.S. officials say

Pharmacists can give childhood shots, U.S. officials say
Pharmacists in all 50 states are now allowed to give childhood vaccinations under a new directive aimed at preventing future outbreaks of measles and other preventable diseases.

Pharmacists can give childhood shots, U.S. officials say

Trail of bubbles leads scientists to new coronavirus clue

Trail of bubbles leads scientists to new coronavirus clue
A doctor checking comatose COVID-19 patients for signs of a stroke instead stumbled onto a new clue about how the virus may harm the lungs -- thanks to a test that used tiny air bubbles and a robot.

Trail of bubbles leads scientists to new coronavirus clue

FDA blocks much-anticipated BioMarin hemophilia gene therapy

FDA blocks much-anticipated BioMarin hemophilia gene therapy
Investors fled drug developer BioMarin in droves on Wednesday, driving shares down by a third after U.S. regulators rejected the company’s potentially game-changing hemophilia A gene therapy over concerns it might not really be a one-and-done lifetime treatment.

FDA blocks much-anticipated BioMarin hemophilia gene therapy